GHRP-6 vs Sermorelin
Well Studied vs Well Studied
synergistic Mechanism-based · 55% GHRP-6 and Sermorelin amplify GH release through complementary mechanisms (GHRH primes, GHRP triggers). This is a well-established synergistic combination — expect significantly greater GH output than either alone.
Molecular Data
GHRP-6 Sermorelin
Weight 873 Da 3,358 Da
Half-life 15-60 minutes 10-12 minutes
Chain 6 amino acids 29 amino acids
Type Synthetic hexapeptide GHRH analog
Key Benefits
GHRP-6
01 Potent stimulation of natural growth hormone release
02 Significant increase in appetite (beneficial for bulking/weight gain)
03 Enhanced muscle growth through elevated GH and IGF-1
04 Improved fat metabolism and body composition
05 Cardioprotective effects observed in research
06 Enhanced recovery from exercise and injury
07 Cytoprotective and anti-inflammatory properties
08 Maintains natural GH pulsatile release
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
GHRP-6
100-300 mcg per injection / 2-3 times daily (morning, post-workout optional, before bed)
GH optimization 100 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Appetite/bulking 100-200 mcg Before meals
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
GHRP-6
Intense hunger/increased appetite (most notable side effect)
Water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetes (use with caution)
WADA prohibited for competitive athletes
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
GHRP-6 Sermorelin
Status Well Studied Well Studied
References 3 studies 5 studies
Latest — November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.